Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 11, Pages 2692
Publisher
MDPI AG
Online
2022-05-30
DOI
10.3390/cancers14112692
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current Clinical Trial Landscape of OX40 Agonists
- (2022) Rashi Yadav et al. Current Oncology Reports
- PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model
- (2021) Won Ick Chang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
- (2020) Guoxuan Gao et al. BMC CANCER
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice
- (2020) Javed Mahmood et al. Cancers
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
- (2019) Nusrat Jahan et al. OncoImmunology
- Immunomodulatory Effects of Stereotactic Body Radiation Therapy (SBRT): Preclinical Insights and Clinical Opportunities
- (2019) Ariel E. Marciscano et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
- (2019) David A Palma et al. LANCET
- Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model
- (2018) Sharareh Niknam et al. CLINICAL CANCER RESEARCH
- Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with De Novo Spinal Metastases treated with Spine Stereotactic Body Radiotherapy (SBRT)
- (2018) Chia-Lin Tseng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms
- (2018) Xiaolong Zhang et al. Cell Reports
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database
- (2018) Ki-Tae Hwang et al. CLINICAL CANCER RESEARCH
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF–expressing tumor cells
- (2017) Nusrat Jahan et al. NEURO-ONCOLOGY
- Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
- (2017) Sathana Dushyanthen et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model
- (2017) Younghee Park et al. Oncotarget
- Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment
- (2017) Yuki Muroyama et al. Cancer Immunology Research
- TREX1 dictates the immune fate of irradiated cancer cells
- (2017) Claire Vanpouille-Box et al. OncoImmunology
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Batf3-dependent CD103+dendritic cell accumulation is dispensable for mucosal and systemic antifungal host defense
- (2016) Timothy J. Break et al. Virulence
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Batf3-dependent CD103+dendritic cells are major producers of IL-12 that drive local Th1 immunity againstLeishmania majorinfection in mice
- (2014) María Martínez-López et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function
- (2013) K. S. Voo et al. JOURNAL OF IMMUNOLOGY
- Interleukin-6 Inhibits Regulatory T Cells and Improves the Proliferation and Cytotoxic Activity of Cytokine-induced Killer Cells
- (2012) Guohe Lin et al. JOURNAL OF IMMUNOTHERAPY
- Science gone translational: the OX40 agonist story
- (2011) Andrew D. Weinberg et al. IMMUNOLOGICAL REVIEWS
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- OX40 is required for regulatory T cell–mediated control of colitis
- (2010) Thibault Griseri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice
- (2010) Michael J. Gough et al. JOURNAL OF IMMUNOTHERAPY
- Identification of the murine firefly luciferase-specific CD8 T-cell epitopes
- (2009) M P Limberis et al. GENE THERAPY
- Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer
- (2008) Hiroshi Yokouchi et al. CANCER SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search